In the News

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012

Rakesh Jain Inducted into the National Academy of Fellows

TAMPA, Fla., Dec. 12, 2017 /PRNewswire/ -- The National Academy of Inventors (NAI) has named 155 renowned academic inventors to NAI Fellow status. With the election of the 2017 class there are now 912 NAI Fellows, representing over 250 research universities and governmental and non-profit research institutes. The 2017 Fellows are named inventors on nearly 6,000 issued U.S. patents, bringing the collective patents held by all NAI Fellows to more than 32,000 issued U.S. patents.
For the 4th year in a row, Rakesh Jain was named a Highly Cited Researcher by Clarivate Analytics / Web of Science. His research ranks among the top 1% most cited works in clinical medicine.
Rakesh Jain Honored at New England Choice Awards Gala
FDA-approved drug may block resistance to anti-angiogenesis therapy
Longitudinal intravital microscopy of murine lymph nodes made possible by chronic optical window

“Deciphering and targeting mechanisms involved in resistance to anti-angiogenic therapy is critical to realizing the full potential of this promising cancer therapy,” says Dai Fukumura, MD, PhD, deputy director of the Steele Labs, co-senior author of the paper. “Not only is this the first report investigating the role in anti-angiogenic cancer therapy of a subset of innate immune cells – Ly6Clowor non-classical monocytes – it is also the first to find an immunosuppressive function for these cells and to identify that as the key mechanism conferring resistance to anti-angiogenic therapy.” 

"What did the lymph nodes show?" is the question whose answer is apprehensively awaited by every colon cancer patient. Even in the age of molecular medicine, the absence or presence of colon cancer spread to regional lymph nodes remains the strongest predictor of whether surgery has cured the cancer, or whether an individucal may harbor occult metastatic disease and thus require adjuvant chemotherapy to reduce the risk of lethal cancer metastasese recurring in distant organs.

Press release ... 
Editorial in Science ...

When Cancer Can't Be Cured, Low-Dose Chemo Aims To Keep It In Check
Instead of starving a cancer, researchers go after its defenses
Protein identified by Mass. General team may protect tumor-initiating cells in breast cancer